Access
To read this story in full you will need to login or make a payment (see right).
News
Nature Medicine 13, 110 (2007)
Published online: 31 January 2007 | doi:10.1038/nm0207-110a
Tied up in red tape, European trials shut down
Brandon Keim1
- New York
Abstract
Uneven rules across Europe have created a bureaucratic nightmare.
The chemotherapy drug doxorubicin has been used to treat soft-tissue cancers in children for more than 20 years, but doctors don't know the most effective dose, nor how it interacts with other drugs.In 2005, European researchers set out to find these answers in a large, multi-center trial.
To read this story in full you will need to login or make a payment (see right).
